Efficacy and Safety of Dexmedetomidine during Anesthesia Induction of Patients with Intracranial Tumor: A Preliminary Observational Trial

Jiangbei Cao, Wenzhu Shi, Weidong Mi, Hong Zhang*

Department of Anesthesiology and Operation Center, PLA General Hospital, Beijing, China.
Email: cjb2000@sina.com, mazuimao301@yahoo.com.cn

Received September 15th, 2013; revised October 16th, 2013; accepted October 25th, 2013

Copyright © 2013 Jiangbei Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: The efficacy and safety of dexmedetomidine during the anesthesia induction of intracranial tumor patients remain unknown. We wondered whether loading infusion of dexmedetomidine 1 µg/kg over 10 min to intracranial tumor patients was as efficient and safe as to those abdominal disease patients. Methods: Patients aged 18 - 60 years, male or female, ASA I or II, scheduled for intracranial tumor resection (Group N, n = 30) or abdominal operation (Group A, n = 30) were enrolled in this observational trial. Dexmedetomidine was administrated with a loading dosage of 1 µg/kg over 10 min following with continuous infusing of 0.5 µg/kg/h. Fentanyl, propofol and rocuronium were sequentially administered for anesthesia induction. Heart rate (HR), blood pressure (BP), pulse oxygen saturation (SpO2), bispectral index (BIS) and other adverse effects were recorded from the beginning of loading infusion of dexmedetomidine to the end of endotracheal intubation.

Results: Among with loading infusion, HR and BIS value decreased and were significantly lower at the end of infusion than before infusion (P < 0.01), but BP did not (P > 0.05). One patient of Group N dropped out from this trial because of a serious headache. 14 of 29 patients during dexmedetomidine loading infusion suffered hypoxemia (SpO2 < 90%) in Group N, which was higher than 6 of 30 of in Group A (P < 0.05). No other side effects were recorded.

Conclusion: A loading dosage of 1 µg/kg of dexmedetomidine was not suitable for the anesthesia induction of intracranial tumor patients as compared to patients undergoing abdominal operation.

Keywords: Dexmedetomidine; Intracranial Tumor; Adverse Effects; Loading Infusion

1. Introduction

Dexmedetomidine, a highly selective α2-adrenoreceptor agonist, is widely used as a sedative or an adjuvant agent for anesthesia induction and maintenance [1-6]. Patients sedated with dexmedetomidine could well tolerate the endotracheal intubation. When using as sedative, dexmedetomidine can increase hemodynamic stability, cause little respiratory depression and allow a rapid recovery [1,7,8].

Preliminary data of the perioperative usage of dexmedetomidine in patients undergoing neurosurgery have indicated that preoperative usage of dexmedetomidine may spare opioid requirements and offer more stable hemodynamics during neurosurgery [9-11]. Besides dexmedetomidine’s well-proven sedative effects, an increasing body of both in vitro and in vivo evidence indicates that dexmedetomidine also exerts a cell-protective effect on nervous tissue under ischemic conditions [12-15].

In addition, laryngoscopy and endotracheal intubation are apt to result in hypertension, tachycardia and arrhythmias, which is hazardous to those patients undergoing neurosurgery for brain tumor [16,17]. Therefore, it seems that dexmedetomidine used as an adjunct of anesthesia induction may be helpful to those patients undergoing neurosurgery. Dexmedetomidine loading infusion with the dosage of 1 µg/kg over 10 min showed its efficacy and safety to several kinds of operation patients [18-20]. However, the efficacy and safety of dexmedetomidine loading infusion during anesthesia induction to
those intracranial tumor patients remain unknown. The objective of this preliminary observational trial was to investigate into the sedative effects, respiration inhibition, hemodynamic changes and adverse effects of dexmedetomidine with a loading infusion dosage 1 μg/kg over 10 min during introduction in neurosurgery patients.

2. Patients and Methods

This trial protocol was approved by the Ethics Committee of the General Hospital of PLA, Beijing, China. The written informed consents were obtained from all patients.

Sixty patients, male or female, aged 18 - 60 years, with American Society of Anesthesiologists (ASA) physical status I or II, were enrolled from April 2011 to October 2011 in this trial. Among these patients, 30 patients were scheduled to intracranial tumor resection (Group N), and the other 30 patients were scheduled for abdominal operation (Group A). The exclusion criteria included: patients with hepatic or renal insufficiency, a history of allergy to α2-adrenoreceptor agonist, a psychiatric or neuromuscular disorder, or predicted difficult airway.

All the patients were premeditated with intramuscular atropine of 0.5 mg at 30 min before operation. After entering the operation room, patients were inserted intravenously catheter with a 20- or 22-gauge in a peripheral vein. The patients were first administered with a loading dosage of 1 μg/kg of dexmedetomidine (200 μg/ml, diluted with normal saline to 4 μg/ml) over 10 min by a computer controlled pump infuser then followed to infuse with the rate of 0.5 μg/kg/h. When loading infusion was ended, fentanyl 2 μg/kg, propofol 2 mg/kg and rocuronium 0.9 mg/kg were sequentially administered within 1 min. Three minutes later, endotracheal intubation was performed by one of the two appointed attending anesthesiologists. Propofol and isoflurane were used for anesthesia maintenance.

Heart rate (HR), blood pressure (systolic and diastolic blood pressure, SBP and DBP), bispectral index (BIS) and pulse oxygen saturation (SPO2) were recorded at the following time points: before dexmedetomidine loading infusion (T1), at the end of loading infusion (T2), before, during and 5 min after endotracheal intubation (T3-5, respectively).

Normally, during the period of loading infusion, the patients inhaled room air without extra-oxygen supplying. If a patient’s HR < 45 bpm for >3 min, SBP < 80 mmHg for >3 min, or SPO2 < 90% for >1 min, he (she) will drop out from this trial and then atropine, ephedrine or 100% oxygen via mask will be given [21]. The occurrence of adverse reactions including nausea and dry mouth were also noted.

3. Statistical Analysis

Data are presented as means ± SD or proportion. Statistical analysis was performed using the SPSS 17.0 software for Windows (Chicago, IL). Proportion was compared using chi-square test. Age, weight and height were compared using independent-samples t tests. HR, SBP, DBP, BIS and SPO2 were analyzed by using analysis of variance for repeated measurements. P < 0.05 was considered to be statistically significant.

4. Result

All the surgeries were successfully completed. One patient from Group N was ceased to continue infusing dexmedetomidine because a severe headache occurred during the loading infusion. There was no significant difference with respect to demographic data between the two groups (Table 1).

As shown in Figure 1, the HR of Group N is faster than that of Group A (83 ± 11 bpm vs. 75 ± 10 bpm, P < 0.01) before anesthesia. After loading infusion of dexmedetomidine at dosage of 1 μg/kg, HR decreased significantly in both groups (the average HR of Group N was 62 bpm and Group A was 61 bpm independently, P < 0.01, compared with T1, Figure 1). However, there was no significant change in blood pressure during loading infusion or even during endotracheal intubation (Figure 2).

Among with the infusion of dexmedetomidine, the patient could be sedated effectively. After loading infusion, it showed that patients were deep sedated (the average BIS value decreased from 94 to 74 in Group N, from 95 to 76 in Group A, P < 0.01, Figure 3). In this trial, we designed that all patients were limited to inhale room air during dexmedetomidine loading infusion. The results showed that at the end of loading infusion SPO2 value decreased from 98% to 95% of Group N and from 99% to 96% respectively (P < 0.01) (Figure 4). Though no patient was dropped off in case of SPO2 lower than 90% for more than 1 minute. However, it happened to some patients of both groups that their SPO2 value were fluctuating between 86% - 96%. Among them, 14 of 29 patients in Group N while 6 of 30 patients in Group A whose SPO2 value dropped below 90% at least once during dexmedetomidine loading infusion (P < 0.05).

<table>
<thead>
<tr>
<th>Table 1. Demographics in the two groups.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
</tr>
<tr>
<td>---------------</td>
</tr>
<tr>
<td>Sex, male/female</td>
</tr>
<tr>
<td>Age, mean (SD), yr</td>
</tr>
<tr>
<td>Weight, mean (SD), kg</td>
</tr>
<tr>
<td>Height, mean (SD), cm</td>
</tr>
</tbody>
</table>
Efficacy and Safety of Dexmedetomidine during Anesthesia Induction of Patients with Intracranial Tumor: A Preliminary Observational Trial

5. Discussion

In this trial, we compared the efficacy of dexmedetomidine in a method of commonly used between neurosurgery and abdominal operation patients. The results showed that BP, SpO2 and BIS had no significantly statistical difference between the two groups. However, during loading infusion of dexmedetomidine with 1 μg/kg over 10 min, the intracranial tumor patients had a higher incidence of hypoxemia (SpO2 < 90%) than those abdominal operation patients, and also dexmedetomidine infusing. In this episode, his SBP increased from 138 to 158 mmHg when headache occurred, and returned to 141 mmHg when headache disappeared.

There was no patient complained of the common adverse reactions in both groups, for example nausea or dry mouth. However, an 18-year-old male patient with pituitary tumor was dropped out from this trial because he suffered a serious headache after dexmedetomidine loading infusion for about 5 min. His headache disappeared within 2 min after the stop of dexmedetomidine loading infusion and endotracheal intubation.
might induce serious headache in patients with intracranial tumor.

Dexmedetomidine as an α2-adrenoeceptor agonist is widely used for the sedation of intubated and mechanically ventilated patients in the intensive care setting, as well as for the sedation of non-intubated patients before and during surgical procedures [7,24,25]. In addition to its sedative properties, dexmedetomidine causes sympatholysis and decreases anesthetic requirements, which may decrease opioid use and make it attractive for use as an adjunct to general anesthesia. Moreover, the neuroprotective property of dexmedetomidine has been demonstrated in various animal models of cerebral ischemia [9,26]. Drummond and colleagues [27] recently demonstrated a simultaneous decrease of CBF and CMRO2 with dexmedetomidine in healthy volunteers. However, the cerebral blood flow (CBF)/cerebral metabolic rate (CMR) ratio did not decrease and suggest that CMR-CBF coupling is preserved during dexmedetomidine administration. Also, researchers found that dexmedetomidine could decrease the adrenergic response to the trauma of surgery and improve perioperative hemodynamic stability [28]. All these documents show that pretreatment or loading infusion with dexmedetomidine before induction has the advantage to those neurosurgery patients.

However, there are few researches on the safety of using dexmedetomidine to intracranial tumor patients and which dosage should be used as an adjunct to anesthesia induction, though it was recommended that dexmedetomidine 1 μg/kg as loading infusion over 10 min was a common clinical dosage [22]. In this study, we designed a trial to investigate the safety and efficiency of dexmedetomidine usage to those intracranial patients who received a loading infusion dosage of 1 μg/kg over 10 min as an adjunct to anesthesia induction. Additionally, patients were allowed to inhale room air but not the 100% O2 during loading infusion during this trial to investigate the dexmedetomidine’ effect on patients’ respiratory function.

The primary composite endpoint of this study was defined as patients having any of the following during loading infusion period: 1) HR < 45 bpm for >3 minutes, 2) systolic blood pressure (SBP) < 80 mmHg for >3 minutes, 3) or SpO2 < 90% for >1 min, or 4) administration of vasoactive agents (including <500 μg phenylephrine by bolus or infusion, any epinephrine) or any atropine. It was found that the HR of almost all the patients was almost the same of both groups at the end of dexmedetomidine loading infusion. However, there was a young man suffered an unpredictable headache. The exact reason for headache happening was far to know, but the occurrence of headache warning us to notice this adverse reaction when dexemdetomidine used in clinics, particularly in patients with intracranial tumor. Sometimes, a higher loading infusion doses may be required to ensure adequate sedation. However, a higher dose of dexmedetomidine can have a higher incidence of hypertension, bradycardia, and hypotension [7,34,35].

Patients with intracranial tumor showed less endurance than those patients without intracranial tumor.

The main limitation of our study was the small sample size.
size. The sample size was too small especially when observing adverse reactions. Therefore, further large sample size investigations are needed in the near future to determine the safety of dexmedetomidine in neurosurgery. Further studies are necessary to establish an optimal dosage regimen especially for patients underwent craniotomy, because those patients maybe always endure a high ICP and experience an unexpected adverse reaction. Secondly, we had not checked the precise sedation scores of patients and also had not recorded the frequent of respiration. Therefore, further investigations maybe need to answer these questions.

6. Conclusion

Compared with those without intracranial tumor patients, dexmedetomidine with a loading dosage 1 μg/kg may induce more serious respiration depression and sometimes headache in intracranial tumor patients. And further investigations with a large sample size are needed to determine the safety range of dexmedetomidine in intracranial tumor patients.

7. Acknowledgements

We thank Dr. Jianjun Yang for reviewing this manuscript.

REFERENCES


[15] R. N. Soliman, A. R. Hassan, A. M. Rashwan and A. M. Omar, “Prospective, Randomized Controlled Study to Assess the Role of Dexmedetomidine in Patients with Supratentorial Tumors Undergoing Craniotomy under General Anesthesia,” Middle East Journal of Anesthesiology,
Efficacy and Safety of Dexmedetomidine during Anesthesia Induction of Patients with Intracranial Tumor: A Preliminary Observational Trial


